Noxopharm Ltd has released a press release.
Noxopharm DARRT-2 Cancer Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
- Licencing Deal Expands Noxopharm Drug Opportunities
- Retraction of Grant Announcement
- Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
- Noxopharm Announces DARRT-2 Clinical Trial in U.S.
Later from Noxopharm
- Noxopharm Announces Leadership Transition
- Noxopharm Receives A$5.865M R & D Tax Rebate
- December 2021 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2022 Financial Report
- First Patient Treated in CEP-2 Sarcoma Trial
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm